Form D · Pharmaceuticals
IMMUNE PHARMACEUTICALS INC
New York, NY · CIK 0001208261
Offering snapshot reported Apr 14, 2014 · SEC filing
- Reported sold
- $11.7M Offering amount: $11.7M
- Investors reported
- 42 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 14, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 14, 2014 | Initial | $11,720,475 | No comparison | 42 | SEC filing |
| Aug 18, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Feb 28, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $545K
- Finders' fees
- $0
- Form D file number
- 021-215479
Sales commissions based only on sales to investors introduced by Chardan Capital Markets LLC
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Chardan Capital Markets LLC | 120128 |
Source: Form D, filed Apr 14, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Daniel Kazado | Director |
| Isaac Kobrin | Director |
| Rene Lerer | Director |
| David Sidransky | Director |
| Ana Stancic | Director |
| Daniel G. Teper | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
708 Third Avenue Suite 210
New York, NY, 10017
New York, NY, 10017